Instil Bio Q2 net loss $3.24/share; cash $103.6M; IND cleared for '2510

Instil Bio, Inc.

2025-Q2 EPS reported -$7.55

Cash, equivalents, marketable securities and long-term investments of $103.6M as of June 30, 2025; funded beyond 2026.
Net loss per share $3.24 (GAAP) and $2.88 (non-GAAP) for Q2 2025, vs $2.29 and $1.57 year-ago.
R&D expenses $6.7M in Q2 2025; in-process R&D expenses $10.0M; G&A expenses $6.2M.
U.S. IND for AXN-2510/IMM2510 cleared; U.S. trial initiation expected before end of 2025.
Appointed Jamie Freedman, M.D., Ph.D. as Chief Medical Officer in June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.